Article info
Student essay
Should mitochondrial replacement therapy be funded by the National Health Service?
- Correspondence to Sophie Rhys-Evans, School of Medicine, University of Liverpool Faculty of Health and Life Sciences, Liverpool L69 3GE, UK; sophie.rhysevans09{at}gmail.com
Citation
Should mitochondrial replacement therapy be funded by the National Health Service?
Publication history
- Received December 26, 2019
- Revised May 14, 2020
- Accepted May 16, 2020
- First published June 23, 2020.
Online issue publication
February 22, 2021
Article Versions
- Previous version (23 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- The need for donor consent in mitochondrial replacement
- A brief and personal history of ‘what’s in a name’ in reproductive genetics
- Mitochondrial replacement techniques for treating infertility
- Britain’s new preimplantation tissue typing policy: an ethical defence
- Lesbian motherhood and mitochondrial replacement techniques: reproductive freedom and genetic kinship
- UK moves a step closer to being first country in world to allow “three parent babies”
- Government gives the go ahead for mitochondrial donation during IVF
- ‘No’ to lesbian motherhood using human nuclear genome transfer
- Nuclear transfer to prevent maternal transmission of mitochondrial DNA disease
- Technique to eliminate mitochondrial disease carries very small risk of failure, researchers find